These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 24126432

  • 1. [Nalmefene: a novel pharmacotherapeutic option for alcoholism].
    Soyka M.
    Nervenarzt; 2014 May; 85(5):578-82. PubMed ID: 24126432
    [Abstract] [Full Text] [Related]

  • 2. Nalmefene for the treatment of alcohol dependence: a current update.
    Soyka M.
    Int J Neuropsychopharmacol; 2014 Apr; 17(4):675-84. PubMed ID: 24246244
    [Abstract] [Full Text] [Related]

  • 3. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [Abstract] [Full Text] [Related]

  • 4. Safety of nalmefene for the treatment of alcohol use disorder: an update.
    López-Pelayo H, Zuluaga P, Caballeria E, Van den Brink W, Mann K, Gual A.
    Expert Opin Drug Saf; 2020 Jan; 19(1):9-17. PubMed ID: 31868031
    [Abstract] [Full Text] [Related]

  • 5. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M, Friede M, Schnitker J.
    Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
    [Abstract] [Full Text] [Related]

  • 6. Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder.
    Milano G, Zavan V, Natta WM, Martelli A, Mattioli F.
    J Clin Pharm Ther; 2016 Feb; 41(1):97-100. PubMed ID: 26714742
    [Abstract] [Full Text] [Related]

  • 7. Treatment of cocaine craving with as-needed nalmefene, a partial κ opioid receptor agonist: first clinical experience.
    Grosshans M, Mutschler J, Kiefer F.
    Int Clin Psychopharmacol; 2015 Jul; 30(4):237-8. PubMed ID: 25647453
    [Abstract] [Full Text] [Related]

  • 8. Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.
    Franchitto N, Jullian B, Salles J, Pelissier F, Rolland B.
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):669-677. PubMed ID: 28343423
    [Abstract] [Full Text] [Related]

  • 9. Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors.
    Korpi ER, Linden AM, Hytönen HR, Paasikoski N, Vashchinkina E, Dudek M, Herr DR, Hyytiä P.
    Addict Biol; 2017 Jul; 22(4):1022-1035. PubMed ID: 26990998
    [Abstract] [Full Text] [Related]

  • 10. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
    Soyka M.
    Expert Opin Pharmacother; 2016 Jul; 17(4):619-26. PubMed ID: 26810044
    [Abstract] [Full Text] [Related]

  • 11. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
    van den Brink W, Strang J, Gual A, Sørensen P, Jensen TJ, Mann K.
    Expert Opin Drug Saf; 2015 Apr; 14(4):495-504. PubMed ID: 25652768
    [Abstract] [Full Text] [Related]

  • 12. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
    Mann K, Bladström A, Torup L, Gual A, van den Brink W.
    Biol Psychiatry; 2013 Apr 15; 73(8):706-13. PubMed ID: 23237314
    [Abstract] [Full Text] [Related]

  • 13. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG.
    Adicciones; 2015 Sep 29; 27(3):214-30. PubMed ID: 26437315
    [Abstract] [Full Text] [Related]

  • 14. Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine.
    Lescut C, Gaboriau L, Carton L, Rolland B.
    J Clin Psychopharmacol; 2017 Oct 29; 37(5):631-633. PubMed ID: 28806388
    [No Abstract] [Full Text] [Related]

  • 15. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
    Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F.
    PLoS Med; 2015 Dec 29; 12(12):e1001924. PubMed ID: 26694529
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Recent Developments in Pharmacotherapy of Alcoholism.
    Soyka M, Lieb M.
    Pharmacopsychiatry; 2015 Jul 29; 48(4-5):123-35. PubMed ID: 25761458
    [Abstract] [Full Text] [Related]

  • 18. Naltrexone: Not Just for Opioids Anymore.
    Sudakin D.
    J Med Toxicol; 2016 Mar 29; 12(1):71-5. PubMed ID: 26546222
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.